Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2020-11-12 Declaration of Voting R…
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document details a transaction involving a holder (Mark Lampert) and an issuer (Calliditas Therapeutics AB), specifically reporting changes in share quantity and voting rights. Key phrases like 'major shareholding notification', 'Before the transaction', 'After the transaction', and the reporting of percentages crossing a threshold (10% limit mentioned) strongly indicate a notification of a significant change in ownership. This aligns directly with the definition of Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2020-11-12 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Calliditas Therapeutics AB covering the period 1 January to 30 September 2020. It contains comprehensive financial data, including income statements, balance sheet summaries, management commentary (VD-ord), and operational updates on clinical trials (NefIgArd). It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2020
2020-11-12 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January 1 – September 30, 2020' and contains detailed financial statements, key figures, management discussion, and business updates for the specified period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-12 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for 'Investinor AS' in 'Calliditas Therapeutics AB'. It explicitly states the 'Reason for major shareholding notification Sell' and provides 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights (0.334 %). This structure is characteristic of a notification regarding a change in significant ownership thresholds. Among the provided codes, 'Major Shareholding Notification' (MRQ) is the most appropriate classification.
2020-11-10 English
Calliditas rapporterar positiva topline-resultat från fas 3-studien NefIgArd
Earnings Release Classification · 100% confidence The document is titled with a headline announcing 'Calliditas rapporterar positiva topline-resultat från fas 3-studien NefIgArd' (Calliditas reports positive topline results from phase 3 study NefIgArd). It details clinical trial results (primary and secondary endpoints, safety profile) for a drug candidate (Nefecon) and outlines future regulatory submission plans (FDA in Q1 2021, EMA in H1 2021). It concludes with a section on 'Om Calliditas' and 'Framåtblickande uttalanden' (Forward-looking statements) and is dated November 8, 2020. This structure is characteristic of an Earnings Release (ER) or a press release announcing significant operational/clinical milestones, which often precedes a formal quarterly report. Since it focuses on the immediate announcement of key results rather than being a comprehensive periodic financial report (10-K or IR), the most appropriate classification is Earnings Release (ER). It is not a transcript (CT), a full annual report (10-K), or a general regulatory filing (RNS) given the specific nature of the announcement. Q4 2020
2020-11-08 Swedish
Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial
Legal Proceedings Report Classification · 99% confidence The document is a press release dated November 8, 2020, announcing 'Positive Topline Results from Pivotal Phase 3 NefIgArd Trial' for the drug Nefecon. It details efficacy data (UPCR, eGFR), safety profile, trial design (Part A and Part B), and future regulatory submission plans (FDA in Q1 2021, EMA in H1 2021). This content strongly aligns with an Earnings Release (ER) which typically includes key operational and clinical milestones alongside financial highlights, or potentially an Investor Presentation (IP) if it were structured as slides, but the format is a formal press release announcing results. Since it focuses on the immediate announcement of period results (clinical trial outcome) rather than a comprehensive annual/interim financial report (10-K/IR) or a management discussion (MDA), 'Earnings Release' (ER) is the most appropriate classification for a major clinical/operational milestone announcement of this nature, especially as it precedes formal regulatory submissions. It is not a transcript (CT), a formal financial report (10-K/IR), or a general regulatory filing (RNS).
2020-11-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.